Intract Pharma and Elasmogen Ltd announce collaboration to discover and develop novel, orally-delivered protein therapeutics | 05.05.2020

Intract Pharma Limited London, UK (“Intract”), and Elasmogen Limited, Aberdeen, Scotland (“Elasmogen”) have announced an agreement to collaborate and develop novel orally-delivered protein therapeutics (biologics), incorporating proprietary technologies developed by each of the partners. The collaboration combines Elasmogen’s soloMER™ technology, small (11 kDa) single-chain  binding domains that can be rapidly re-formatted to generate super-neutralizers (bivalent, […]